Compare CSTL & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTL | GAU |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 680.7M |
| IPO Year | 2019 | 2006 |
| Metric | CSTL | GAU |
|---|---|---|
| Price | $24.32 | $2.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $47.17 | $4.08 |
| AVG Volume (30 Days) | 261.5K | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | $82.77 |
| Revenue Next Year | $12.69 | $29.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $1.22 |
| 52 Week High | $44.28 | $3.62 |
| Indicator | CSTL | GAU |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 53.45 |
| Support Level | $21.77 | $2.38 |
| Resistance Level | $26.19 | $2.74 |
| Average True Range (ATR) | 1.16 | 0.11 |
| MACD | 0.22 | 0.05 |
| Stochastic Oscillator | 56.85 | 88.14 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.